Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Clariant boosts US pharmaceutical production with Clear Lake expansion

The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged

Trial milestone sparks hope for first long-term gastroparesis treatment

The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

Cupid unveils “Made in India, Japanese Quality” branding to boost global presence

The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer

L&T Tech unveils AI-powered lung digital twin platform

LTTS’ lung digital twin integrates seamlessly with CT imaging workflows, using deep learning to reconstruct a comprehensive 3D digital twin of the lungs

Johnson & Johnson reports promising early results for targeted bladder cancer therapy

FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors